维普期刊资源整合服务平台（V6.5）

101篇 您的检索式：作者名="Sandborn P"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America:a systematic review显示文摘	Loftus EV Jr Schoenfeld P Sandborn WJ	2002	Aliment Pharmacol Ther2002，16，1：	1
2	Infliximab forinduction and maintenance therapy for ulcerative colitis显示文摘	RUTGEERTS P SANDBORN W J FEAGAN B G	2005	NEngl J Med2005，353，23：	1
3	The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review 显示文摘	SCHOENFELD P SANDBORN W J	2002	Aliment Pharmacol Ther2002，16，1：	1
4	Infliximab for induction and maintenance therapy for ulcerative colitis显示文摘	Rutgeerts P Sandborn W J Feagan B G		New England Journal of Medicine0，，：	1
5	The epidemiology and natural history of Crohn's disease in population-based pa- tient cohorts from North America: a systematic review 显示文摘	Loftus EV Schoenfeld P Sandborn WJ	2002	Aliment Pharmaeol Ther2002，16，：	1
6	Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial显示文摘	COLOMBEL J SANDBORN WJ RUTGEERTS P	2007	Gastroenterology2007，132，1：	1
7	The epidemiology and natural history of crohn's disease in population based patient cohorts from North America: a systematic review显示文摘	Loftus E V Schoenefld P Sandborn W J	2002	Aliment Pharmacol Ther2002，16，1：	1
8	Infliximabfor induction and maintenance therapy for ulcerative colitis 显示文摘	Rutgeerts P Sandborn WJ Feagan BG	2005	N Engl J Med2005，353，23：	1
9	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial显示文摘	SANDBORN WJ HANAUER SB RUTGEERTS P	2007	Gut2007，56，9：	1
10	Human antl-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease : The CLASSIC-I Trial显示文摘	HANAUER SB SANDBORN WJ RUTGEERTS P	2006	Gastroenterology2006，130，2：	1
11	A data mining based approach to electronic part obsolescence forecasting 显示文摘	Sandborn P A Mauro F Knox R	2007	IEEE Trans on Components and Packaging Tech2007，9，3：	1
12	Infliximab for induction and maintenance therapy for ulcerative colitis 显示文摘	Rutgeerts P Sandborn WJ Feagan BG	2005	N Engl J Med2005，353，23：	1
13	IOIBD technical re- view on endoscopic indices for Crohn's disease clinical trials 显示文摘	Vuitton L Marteau P Sandborn WJ	2015	Gut2015，，：	1
14	Adalimumab safety in Crohn's disease patients: open-label maintenance following the GAIN and CHARM trials 显示文摘	COLOMBEL JF RUTGEERTS P SANDBORN WJ	2007	Am J Gastroenterol2007，102，2：	1
15	Review article:treatment algorithms to maximize remission andminimize corticosteroid dependence in patients with inflammatory bowel disease显示文摘	Panaccione R Rutgeerts P Sandborn WJ	2008	Aliment Pharmacol Ther2008，28，：	1
16	Review article : treat- ment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease显示文摘	Panaccione R Rutgeerts P Sandborn W J	2008	Aliment Pharmacol Ther2008，28，：	1
17	Infliximab for induction and maintenance therapy for ulcerative colitis 显示文摘	Rutgeerts P Sandborn WJ Feagan BG	2005	N Engl J Med2005，353，23：	1
18	Electronic part life cycle concepts and obsolescence forecasting显示文摘	Solomon R Sandborn P A Pecht M G	2000	Components and Packaging Technologies2000，23，4：	1
19	Infliximab for induction and maintenance therapy for ul- cerative colitis 显示文摘	Rutgeerts P Sandborn WJ Reinisch W	2005	N Engl J Med2005，353，12：	1
20	Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation显示文摘	KANE S V SANDBORN W J RUFO P A	2003	Am J Gastroenterol2003，98，6：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示